The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8<sup>+</sup>T cell responsesRobert J. Johnston(Johns Hopkins University), Jane L. Grogan(Biogen (United States)), Xin Yu(Amgen (United States))OncoImmunologyMay 27, 201510.1080/2162402x.2015.1036214Cited by 50SaveCiteExport RISWatch citationsRelated PapersSingle-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer|Cell|2020|1.6kLineage tracking reveals dynamic relationships of T cells in colorectal cancer|Nature|2018|1.5kThe surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells|Nature Immunology|2008|1.5kThe Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function|Cancer Cell|2014|1.1kIntratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer|Cancer Cell|2022|403